Home Infusions for Inflammatory Bowel Disease Are Safe: US Experience and Patient Perspectives.

ABSTRACT:

Background

Home infusions (HIs) for biologic medications are an option for inflammatory bowel disease (IBD) patients in the United States. We aimed to describe the population receiving HIs and report patient experience with HIs.

Methods

We conducted a retrospective cohort study in the Quintiles-IMSLegacy PharMetrics Adjudicated Claims Database from 2010 to 2016 to describe the population receiving infliximab (IFX) and vedolizumab (VDZ) HIs and determine predictors for an urgent/emergent visit post-HIs. We then administered a cross-sectional survey to IBD Partners Internet-based cohort participants to assess knowledge and experience with infusions.

Results

We identified claims for 11 892 conventional IFX patients, 1573 home IFX patients, 438 conventional VDZ patients,

SUBMITTER: Kochar B 

PROVIDER: S-EPMC8600957 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature